CBO: Finance Panel’s wellness bill pricetag is $829 billion over a decade; provides coverage to 91 percent of U.S. The Wall Road Journal: ‘The latest health-overhaul expenses from the Senate will definitely cost $829 billion over a decade and provide insurance coverage to 91 percent of U.S. Residents, according to an analysis released Wednesday by the Congressional Budget Office. But the estimate of how far it will broaden insurance coverage is leaner than what Finance Committee Chairman Max Baucus had targeted.’ The expense of the measure is definitely offset by ‘slicing hundreds of billions from federal government health programs such as Medicare and by imposing a 40 % excise tax on high-cost plans starting in 2013.’ Finance panel members have already been anxiously awaiting the CBO’s assessment as they prepare for a final vote .Furthermore, brand-new upcoming drugs, investment by government on Health care and also competitive pressures have been significantly changing the marketplace. Revenues from the anti-cancer drug marketplace in the Asia are anticipated to expand to USD ~ million in 2019 developing with a CAGR of ~ percent from 2014-2019. Important Topics Covered in the Statement: The market size of the oncology medication market in Asia The market size of the patented and generic medications in Asia oncology drug market. The market size of the global and local players market Asia oncology drug marketplace. The marketplace size of the India oncology and China oncology drug market. Market segmentation of the oncology market based on type of cancer, by generic and patented medicines. SWOT and Porter Five force Analysis of India and China Oncology Drug market.